Drugmakers in China Face U.S. Scrutiny

Drugmakers in China Face U.S. Scrutiny Play

Dec. 11 (Bloomberg) –- Bloomberg’s Mia Saini reports on the U.S. supervising more closely the active ingredients in drugs that China supplies, with the FDA tripling the number of regulators in the country. She speaks to Angie Lau on Bloomberg Television’s “First Up.” (Source: Bloomberg)

  • On Air Now

    The Pulse Watch Now

  • Next

    Bloomberg Surveillance

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus